Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.

Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. · 2022

Read Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. by Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8820829.txt.

Introduction

Wen and co-authors pool trial results for three oral antiviral drugs against COVID-19. The drugs are molnupiravir, fluvoxamine, and Paxlovid. Their meta-analysis asks whether these pills cut deaths or hospital stays. It also asks whether they raise side effects. The search covered major medical databases. Eight studies met the criteria for pooling.

The drug groups held 2,440 patients, and the control groups held 2,348. Death or hospital admission struck 54 patients on the drugs and 118 on control care. The pooled odds ratio was 0.33, a cut of about 67%. Side effects did not rise on the drugs. The authors read this as good safety. They call the three drugs a hopeful path for COVID-19 care.

Catalog record

CREATORWen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8820829

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis By Wen Wen, Chen Chen, Jiake Tang, Chunyi Wang, Mengyun Zhou, Yongran Cheng, Xiang Zhou, Qi Wu, Xingwei Zhang, Zhanhui Feng, Mingwei Wang, Qin Mao Published in: Annals of Medicine DOI: 10.1080/07853890.2022.2034936 ABSTRACT Abstract Background The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a simple oral antiviral drug for COVID-19 has not yet been developed. We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid). Methods We searched scientific and medical databases, such as PubMed, Web of Science, Embase and Cochrane Library for relevant articles and screened the references of retrieved studies on COVID-19. Results A total of eight studies were included in this study. The drug group included 2440 COVID-19 patients, including 54 patients who died or were hospitalized. The control group included a total of 2348 COVID-19 patients, including 118 patients who died or were hospitalized. The overall odds ratio (OR) of mortality or hospitalization was 0.33 (95% confidence interval [CI], 0.22–0.49) for COVID-19 patients in the drug group and placebo group, indicating that oral antiviral drugs were effective for COVID-19 patients and reduced the mortality or hospitalization by approximately 67%. Conclusions This study showed that three novel oral antivirals (molnupiravir, fluvoxamine and Paxlovid) are effective in reducing the mortality and hospitalization rates in patients with COVID-19. In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety. These three oral antiviral drugs are still being studied, and the available data suggest that they will bring new hope for COVID-19 recovery and have the potential to be a breakthrough and very promising treatment for COVID-19. - Many antiviral drugs have shown good therapeutic effects, and there is no simple oral antiviral drug for COVID-19 patients. - Meta-analysis was conducted for three new oral antivirals to evaluate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients. - We focussed on three new oral Coronavirus agents (molnupiravir, fluvoxamine and Paxlovid) and hope to provide guidance for the roll-out of oral antivirals. Keywords: COVID-19, molnupiravir, fluvoxamine, Paxlovid™ INTRODUCTION In December 2019, COVID-19 caused by severe acute respiratory syndrome coronavirus type 2 (SARS-COV-2) broke out in China. The COVID-19 epidemic has rapidly spread across the globe, with 251,788,329 cases of COVID-19 and 5,077,907 deaths reported as of 12 November 2021 [1]. Development of a vaccine against the COVID-19 virus has continued, and mass vaccination campaigns are still going on. A study in Italy has shown that COVID-19 vaccine can effectively reduce the mortality of COVID-19 infected patients [2]. As of 12 November 2021, more than 2.3 billion novel coronavirus vaccine doses were given to people in China [3]. However, studies have shown that even vaccinated people are infected with novel coronavirus variants. Millions of immunocompromised patients may not be fully protected after vaccination, and existing vaccines may not be effective against new novel coronavirus variants [4,5]. Although an antiviral drug Remdesivir has been developed that has shown good effects in antiviral therapy [6], some clinical trials have not fully demonstrated its beneficial effects on SARS-COV-2; moreover, the drug is expensive and must be administered intravenously in a hospital setting [6–8]. Therefore, it is essential to develop simple oral coronavirus drugs. Recently, three new oral coronavirus drugs have shown effective results in clinical studies. Recently, molnupiravir, an orally active RdRp inhibitor with a favourable pharmacokinetic profile, has received considerable attention owing to its ability to inhibit SARS-COV-2 replication, remove SARs-COV-2 rapidly, reduce viral load and recover fast [4]. Molnupiravir is the isopropyl ester prodrug of the ribonucleoside analogue β-D-N4-hydroxycytidine (NHC) [9]. An in vitro evidence shows that molnupiravir is a potent inhibitor of SARS-CoV-2 replication with an EC50 in the submicromolar range [9–11]; the effect of this antiviral injection was also observed in animal models [9,12,13]. A study showed that the time taken for viral RNA clearance decreased, and a greater proportion of overall clearance was achieved in participants administered with molnupiravir vs. placebo [14]. In addition, molnupiravir has shown promising efficacy and safety in phase I/II/III clinical trials. Studies have shown that molnupiravir reduces the risk of hospitalization or death by approximately 50% in non-hospitalized adults with mild-to-moderate COVID-19 disease who are at risk for poor prognosis, and the incidence of any adverse events was comparable between the two groups (35 and 40%, respectively), as was the incidence of drug-related adverse events (12 and 11%, respectively) [15]. Fluvoxamine, another oral medication and a selective serotonin reuptake inhibitor and σ-1 receptor agonist [16], has shown potential of early outpatient treatment of COVID-19 in previous studies [17–19] and also good safety and effectiveness in patients in intensive care unit (ICU) [16]. Seftel and Boulware showed that no hospitalization occurred in the fluvoxamine group, while six patients out of the 48 control patients required hospital admission [17]. In addition, prospective cohort trials of fluvoxamine in ICU patients showed an overall mortality rate of 58.8% (n = 30/51) in the fluvoxamine group compared with 76.5% (n = 39/51) in the control group [16]. Paxlovid is an investigational SARS-CoV-2 protease inhibitor antiviral therapy developed by Pfizer Inc., specifically designed to be administered orally [20]. Their recent study showed that Paxlovid reduced the risk of hospitalization or death by 89% [20]. At present, clinical studies on these three oral coronavirus drugs are continuing; better results are expected. We conducted this meta-analysis to further evaluate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with these three oral antiviral drugs (molnupiravir, fluvoxamine and Paxlovid) and hope to provide guidance for the rollout of these oral antivirals. MATERIALS AND METHODS Search strategy We searched scientific and medical databases PubMed, Web of Science, Embase and Cochrane Library for relevant studies. We screened the references of the retrieved studies and restricted the language of the search to English. Following keywords were used in the search: COVID-19 (SARS-CoV-2, novel coronavirus 2019 and 2019-nCoV), molnupiravir (EIDD-2801/MK-4482), fluvoxamine and Paxlovid (PF-07321332; ritonavir). Inclusion and exclusion criteria The inclusion criteria were as follows: (1) the article reported the clinical results of three oral COVID-19 drugs, including the total number of participants and the specific number of deaths or hospitalizations; (2) English literature. The exclusion criteria were as follows: (1) irrelevant to the research direction, (2) no relevant data and (3) repeated literature. Data extraction A total of eight studies were included in this study. The following data were collected: name of the first author, year of publication, name of the study drug, total number of subjects, and number or proportion of deaths or hospitalizations occurring or incidence of any other adverse events. Statistical analysis All statistical analyses were performed using Review Manager version 5.2 software , and a binary controlled study was used to calculate the number of deaths or hospitalizations of COVID-19 patients in the oral antiviral group and placebo group, as well as the incidence of adverse events. Odds ratio (OR)

Read the complete text